The differentiation between residual and non-residual ctDNA, along with the interpretation of PD-L1 expression and the density of infiltrating CD8+ T lymphocytes, highlights the importance of integrating genetic and immunological findings into NSCLC treatment [55,59,60]. Here, CD8A is linked to non-small cell lung carcinoma.